Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 741 results for "biocon"

Investors reposed faith in our growth prospects: Syngene

Readying to list its shares after a bumper 32-times over-subscribed IPO, biotechnology major Biocon's research arm Syngene today said the investors have reposed faith in its future growth prospects. Money Control, 8 hours ago

176 images for biocon

Times of India, 3 days ago
NDTV Profit, 5 days ago
Pharma Letter, 3 days ago
Financial Express, 5 days ago
Oneindia, 6 days ago, 4 days ago
Financial Express, 6 days ago
NDTV Profit, 6 days ago
Money Control, 6 days ago
MSN India, 6 days ago

Syngene IPO subscribed 32.05 times

Biocon's contract research services arm's initial public offer, which opened July 27, found much favour with investors, who bid for more than 32 times the available shares on offer. Biocon had set a price of Rs 240-250 per share, and planned to ...
 Smart Investor14 hours ago First pharma IPO in 5 years: Syngene's debut offer subscribed 32 times  Economic Times22 hours ago Syngene IPO subscribed nearly 32 times  Business Standard India1 day ago Syngene’s debut offer subscribed 32 times  Economic Times23 hours ago
The Freepress Journal

Syngene IPO subscribed 31.7 times on final day [Mint, New Delhi]

July 29--MUMBAI -- The initial public offer (IPO) of Syngene International Ltd, a research arm of Biocon Ltd At 4.10pm, the IPO had received bids for 506.9 million shares against the total issue size of 16 million shares, National Stock Exchange ...
 Bloomberg1 day ago Syngene IPO opens today [Mint, New Delhi]  Bloomberg3 days ago Syngene IPO opens on July 27  The Freepress Journal1 week ago Will Syngene IPO benefit Biocon's valuations?  Livemint.com2 weeks ago
VC Circle

IVFA-backed Syngene's IPO oversubscribed 31 times

Syngene International Ltd, the research and development subsidiary of Indian biopharmaceutical major Biocon Ltd, saw its initial public offer (IPO) covered 32 times or recorded oversubscription of 31 times at the end of the issue. The bumper ...
 VC Circle1 day ago Syngene IPO oversubscribed 31 times  Hindu Business Line10 hours ago Most brokerages vote positive on Syngene IPO  Deccan Herald5 days ago
India Infoline

Top Corporate news of the day

Biocon's research arm Syngene International's initial public offering was over-subscribed. The Food and Drugs Administration of Maharashtra told the Bombay High Court that Maggi noodles manufacturer Nestle India violated laws with the lead level in the ...
 India Infoline1 day ago Apply for Syngene IPO with long term view: Nirmal Bang  Moneycontrol.com2 days ago Syngene IPO subscribed 32% on Day 1  Hindu Business Line3 days ago Biocon shares up over 1.7% on strong Q1 results24-07-2015  Pharma Letter3 days ago
Yahoo! India

Biocon net up 23 pc in Q1

Biotechnology major Biocon Ltd on Thursday reported net profit of Rs.126 crore for the first quarter of 2015-16, posting 23 percent year-on-year (YoY) growth from Rs.103 crore in the same period last year Consolidated revenue for Q1 under review grew 15 ...
 SME Times6 days ago Hillary Clinton says her summer job at a fish-processing plant was the 'best preparation for being in …  Yahoo! India1 week ago How a man who left the US with $400 in his pocket built a career out of seeing the world  Yahoo! India1 week ago Biocon net up 23 percent in Q1  Prokerala1 week ago

Biocon: Outcome of AGM

Biocon Ltd has informed BSE that the 37th Annual General Meeting (AGM) of the Company was held on July 24, 2015.
 Money Control2 days ago Biocon's AGM on July 24, 2015  Money Control2 weeks ago Biocon to hold board meeting  Business Standard3 weeks ago Biocon to hold AGM  Business Standard1 month ago

Fears Over Museum Takeover Plan

BENGALURU: Uncertainty is brewing at Visvesvaraya Industrial and Technological Museum (VITM), following a proposal by Biocon Chairman Kiran Mazumdar-Shaw to adopt it under its Corporate Social Responsibility programme. These fears were in full ...
 New Indian Express2 days ago 'Visvesvaraya museum not a govt property'  Deccan Herald3 days ago

Syngene's valuations are fair, investors need to invest in its growth story: Kiran Mazumdar-Shaw

In an interview with ET Now, Kiran Mazumdar-Shaw, CMD, Biocon, talks about the Syngene IPO and the growth prospects. Excerpts: ET now: Were you nervous about entering the capital market? Kiran Mazumdar-Shaw: I was never nervous about going to ...
 Economic Times3 days ago
Business Standard

US-Cuba handshake brings smiles at Biocon

Drug maker says better poised to licence and position its novel molecule Itolizumab, which has a Cuban origin
 DNA5 days ago Biocon eyes US market for psoriasis drug post US-Cuba thaw  Business Standard India6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - biocon
Get updated on latest news & your favorite topics right in your inbox!
More     Less